相关实验视频

Updated: Nov 26, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

对SARS-CoV-2盐化变异BA.2.87.1的抗原性评估

Sijie Yang^1,2,3, Yuanling Yu², Fanchong Jian^1,2,4

¹Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.

Emerging microbes & infections

|April 15, 2024

概括

新的SARS-CoV-2变种BA.2.87.1显示出有限的免疫逃避,使其易受一些中和抗体的影响. 它可能不会在没有进一步的受体结合域突变的情况下广泛传播.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

新型严重急性呼吸综合征冠状病毒2 (SARS-CoV-2) 变种的出现构成了持续的公共卫生挑战.
与BA.2相比,BA.2.87.1变异的特征是65个尖端突变,由于其对传播和免疫逃逸的潜在影响,引起了全球的重大关注.

研究的目的:

调查SARS-CoV-2变种BA.2.87.1.1.8的抗原性质和免疫逃避能力.
为了比较BA.2.87.1对其他变体 (如XBB和JN.1等) 诱导的幽默免疫的易感性.
评估治疗中和抗体对 BA.2.87.1.1.保持有效性的潜力.

主要方法:

对BA.2.87.1.1.的抗原特征.
对抗 BA.2.87.1.1. 的中和抗体活性的评估.
对受体结合域 (RBD) 和N端域 (NTD) 影响免疫逃避的突变的分析.
评估特定中和抗体药物的疗效.

主要成果:

BA.2.87.1对XBB诱导的幽默免疫具有比JN.1.更大的敏感性.
尽管N端域 (NTD) 的缺失赋予了一些耐药性,但BA.2.87.1缺乏关键受体结合域 (RBD) 突变,无法显著免疫逃脱.
包括SA58,REGN-10933和COV2-2196在内的几种中和抗体显示出对BA.2.87.1.1的恢复有效性.

结论:

BA.2.87.1目前的抗原特征表明其广泛传播的可能性有限.
变种对中和抗体的敏感性可能会通过获得额外的RBD突变来克服,类似于JN.1中看到的免疫逃避.
针对SARS-CoV-2的治疗干预措施可能会保持对BA.2.87.1的有效性,等待进一步的病毒演变.

关键词:

这就是SARS-CoV-2病毒.幽默免疫力幽默免疫力免疫系统逃脱,逃离免疫系统.中和抗体中和抗体.盐分的变种是盐分的变种

更多相关视频

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

相关概念视频

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...